These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21152861)

  • 61. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.
    Gao L; Shao T; Zheng W; Ding J
    Clin Transl Oncol; 2021 Jul; 23(7):1386-1393. PubMed ID: 33566305
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
    Shen X; Zhi Q; Wang Y; Li Z; Zhou J; Huang J
    Chemotherapy; 2017; 62(3):172-180. PubMed ID: 28351036
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
    Srirangam A; Milani M; Mitra R; Guo Z; Rodriguez M; Kathuria H; Fukuda S; Rizzardi A; Schmechel S; Skalnik DG; Pelus LM; Potter DA
    J Thorac Oncol; 2011 Apr; 6(4):661-70. PubMed ID: 21270666
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
    Fang DD; Cao J; Jani JP; Tsaparikos K; Blasina A; Kornmann J; Lira ME; Wang J; Jirout Z; Bingham J; Zhu Z; Gu Y; Los G; Hostomsky Z; Vanarsdale T
    Front Med; 2013 Dec; 7(4):462-76. PubMed ID: 23820871
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
    Chen Y; Qian X; Liu B
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):421-8. PubMed ID: 21569648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
    Feng J; Xu L; Ni S; Gu J; Zhu H; Wang H; Zhang S; Zhang W; Huang J
    Oncotarget; 2014 Oct; 5(20):9689-702. PubMed ID: 25356753
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
    Zeng HZ; Qu YQ; Liang AB; Deng AM; Zhang WJ; Xiu B; Wang H; Wang H
    Neoplasma; 2011; 58(5):449-54. PubMed ID: 21745000
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
    Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib.
    Kwon T; Rho JK; Lee JC; Park YH; Shin HJ; Cho S; Kang YK; Kim BY; Yoon DY; Yu DY
    Exp Mol Med; 2015 May; 47(5):e165. PubMed ID: 26021759
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Determinants of response and resistance to cytotoxics.
    Rosell R; Monzó M; Alberola V; Taron M; Barnadas A; Sánchez JM; Manzano JL; Sanchez JJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):110-8. PubMed ID: 11894021
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
    J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
    Lv C; Ma Y; Feng Q; Fang F; Bai H; Zhao B; Yan S; Wu N; Zheng Q; Li S; Chen J; Wang J; Feng Y; Wang Y; Pei Y; Fang J; Yang Y
    World J Surg Oncol; 2013 Apr; 11():96. PubMed ID: 23621919
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Siena L; Cipollina C; Di Vincenzo S; Ferraro M; Bruno A; Gjomarkaj M; Pace E
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):705-716. PubMed ID: 29435611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.